Sector News

Gilead’s huge Sovaldi payoff yields a nice 23% pay hike for CEO

March 31, 2015
Life sciences
No one would say Gilead Sciences CEO John Martin is hurting financially. For several years, he has collected annual compensation worth about $15 million. Not too shabby. And his stock gains since 2009 run into the hundreds of millions–yes, hundreds.
 
But for a record-smashing year that vaulted his company into the ranks of the global top 10, Martin snared a comparatively small payoff.
 
True, Martin’s 2014 compensation grew by $3.5 million, to almost $19 million. That’s a 23% increase. His base salary amounted to $1.6 million, his options were worth $5.2 million, and his stock awards hit $8.4 million. Cash incentive pay was an impressive $3.72 million.
 
Plus, according to Gilead’s proxy statement, the payoff from stock options he exercised last year was more than $158 million. Again, who’d feel sorry for a guy with that kind of compensation package? Certainly not the patient advocates who protest Gilead’s aggressively high prices.
 
But for a biotech CEO with a record-smashing year, that $18.5 million is, well, conservative. For the most obvious example, look at Regeneron. When the company’s blockbuster eye drug Eylea hit the market by storm in 2012, CEO Len Schliefer collected $26.6 million worth of options and $30 million in total pay. R&D chief George Yancopoulos scored an even bigger sum; his 2012 compensation amounted to $81.5 million. That’s including $21 million in options, plus a $57 million retention grant aimed at keeping him in place through 2017.
 
Or United Therapeutics, which gave CEO Martine Rothblatt a $36 million equity award in 2013, ostensibly to bring her compensation up to par with that of her peers. No big-time launch that year, no major payoff for shareholders–but the board decided the company’s ongoing performance, compared with that of its rivals, was strong enough to put Rothblatt in the 75th percentile, compensation-wise.
 
Or Valeant Pharmaceuticals, which handed CEO J. Michael Pearson $12.2 million in stock awards for his M&A-fueled growth record–and that was for 2011, before Valeant bought Medicis, Bausch & Lomb, or Obagi. That year, he also got a $13.9 million dividend agreed on in 2008, back when Valeant and Biovail merged. His total for 2011? More than $36 million.
 
Or Allergan, the company Valeant tried to buy until Actavis swooped in with a higher offer. CEO David Pyott got a “one-time special” share award in 2012, worth $9.4 million at the time. The extra boost recognized Pyott for boosting the company’s market value by $30 billion since taking over the CEO chair–and because it wouldn’t vest till 2017, was a retention bonus, too. Under the terms of its merger with Actavis, Allergan will accelerate vesting of its share awards–including Pyott’s.
 
We are not arguing for Gilead to give Martin and his execs a major windfall. His $3.5 million raise for 2015 simply illustrates how one company’s compensation committee can make wildly different decisions from another’s, and both say they emphasize compensation that rewards CEOs and their colleagues for performance. Some are mavericks. Others, not so much. To be fair, most pharma companies don’t hand out big, one-time share awards.
 
So, executive pay may purportedly follow some rhyme and reason, but that all depends on who’s dictating the rhyme scheme. And frankly, put all these top-earning CEOs in the EU, and shareholders would be marching in the streets.
 
By Tracy Staton
 

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend